Renaissance Technologies LLC Has $34,000 Stock Position in Genelux Co. (NASDAQ:GNLX)

Renaissance Technologies LLC lowered its position in shares of Genelux Co. (NASDAQ:GNLX - Free Report) by 88.1% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 14,551 shares of the company's stock after selling 107,986 shares during the quarter. Renaissance Technologies LLC's holdings in Genelux were worth $34,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the business. Apollon Wealth Management LLC lifted its position in shares of Genelux by 20.4% during the fourth quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company's stock worth $40,000 after purchasing an additional 2,857 shares in the last quarter. LifeSteps Financial Inc. increased its position in shares of Genelux by 11.1% during the fourth quarter. LifeSteps Financial Inc. now owns 86,970 shares of the company's stock worth $205,000 after acquiring an additional 8,715 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of Genelux in the fourth quarter worth about $25,000. Raymond James Financial Inc. purchased a new position in Genelux in the fourth quarter valued at about $41,000. Finally, D.A. Davidson & CO. acquired a new position in shares of Genelux in the 4th quarter valued at approximately $51,000. Hedge funds and other institutional investors own 37.33% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on GNLX shares. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 price target on shares of Genelux in a report on Monday, March 31st. Benchmark lowered their price objective on Genelux from $25.00 to $23.00 and set a "speculative buy" rating for the company in a report on Thursday, May 8th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Genelux presently has a consensus rating of "Buy" and an average target price of $17.75.

Genelux Stock Down 1.7%

NASDAQ:GNLX traded down $0.04 during mid-day trading on Wednesday, reaching $2.44. 72,170 shares of the company were exchanged, compared to its average volume of 213,424. The company has a fifty day moving average of $2.92 and a 200 day moving average of $3.11. The stock has a market cap of $92.04 million, a PE ratio of -2.57 and a beta of -0.33. Genelux Co. has a 12 month low of $1.60 and a 12 month high of $5.89.

Genelux (NASDAQ:GNLX - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.03. On average, equities research analysts anticipate that Genelux Co. will post -0.88 EPS for the current fiscal year.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.